Physician profile
Naveen Devabhaktuni
NPI 1679586705
$3,378.37
in general payments reported to CMS, 2019-2025
21 companies · $425 in 2025
The $425 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $236 · 2021: $709 · 2022: $482 · 2023: $655 · 2024: $558 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,637.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $635.20 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $583.19 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $368.56 | 2019-2025 | Camzyos, Cobenfy, Eliquis |
| Merck Sharp & Dohme LLC | $303.55 | 2021-2025 | Verquvo |
| Boston Scientific Corporation | $185.58 | 2020-2025 | Watchman Access System, Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $180.80 | 2019-2025 | Lifevest |
| Amgen INC. | $167.39 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.57 | 2021-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $128.39 | 2025 | |
| Abiomed | $127.97 | 2019 | |
| Pfizer INC. | $112.17 | 2021-2025 | |
| Esperion Therapeutics, INC. | $73.06 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $66.45 | 2019-2024 | Brilinta |
| Irhythm Technologies, INC. | $60.39 | 2023 | Zio Xt Patch |
| Astellas Pharma US INC | $59.13 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $58.99 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $38.82 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $34.73 | 2019-2023 | |
| Novo Nordisk INC | $22.45 | 2025 | Ozempic |
| Inspire Medical Systems, INC. | $13.50 | 2023 | Inspire |
| Kiniksa Pharmaceuticals, LTD. | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naveen Devabhaktuni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.